Precision microbiota therapy for IBD: premise and promise
Open Access
- 7 April 2025
- journal article
- review article
- Published by Taylor & Francis in Gut Microbes
- Vol. 17 (1) , 2489067
Abstract
Inflammatory Bowel Disease (IBD) is a spectrum of chronic inflammatory diseases of the intestine that includes subtypes of ulcerative colitis (UC) and Crohn's Disease (CD) and currently has no cure. While IBD results from a complex interplay between genetic, environmental, and immunological factors, sequencing advances over the last 10-15 years revealed signature changes in gut microbiota that contribute to the pathogenesis of IBD. These findings highlight IBD as a disease target for microbiome-based therapies, with the potential to treat the underlying microbial pathogenesis and provide adjuvant therapy to the emerging spectrum of advanced therapies for IBD. Building on the success of fecal microbiota transplantation (FMT) for Clostridioides difficile infection, therapies targeting gut microbiota have emerged as promising approaches for treating IBD; however, unique aspects of IBD pathogenesis highlight the need for more precision in the approach to microbiome therapeutics that leverage aspects of recipient and donor selection, diet and xenobiotics, and strain-specific interactions to enhance the efficacy and safety of IBD therapy. This review focuses on both pre-clinical and clinical studies that support the premise for microbial therapeutics for IBD and aims to provide a framework for the development of precision microbiome therapeutics to optimize clinical outcomes for patients with IBD.Keywords
Funding Information
- NIH/NIDDK
This publication has 119 references indexed in Scilit:
- Prophylaxis of pouchitis onset with probiotic therapy: a double-blind, placebo-controlled trialGastroenterology, 2003
- Mucosal flora in inflammatory bowel diseaseGastroenterology, 2002
- Treatment of recurrent Clostridium difficile-associated diarrhea by administration of donated stool directly through a colonoscopeAmerican Journal of Gastroenterology, 2000
- Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: A double-blind, placebo-controlled trialGastroenterology, 2000
- Presence of adherent Escherichia coli strains in ileal mucosa of patients with Crohn's diseaseGastroenterology, 1998
- Early lesions of recurrent Crohn's disease caused by infusion of intestinal contents in excluded ileumGastroenterology, 1998
- An antibiotic regimen for the treatment of active Crohn's disease: a randomized, controlled clinical trial of metronidazole plus ciprofloxacin.1996
- Effect of faecal stream diversion on recurrence of Crohn's disease in the neoterminal ileumThe Lancet, 1991
- Digoxin-Inactivating Bacteria: Identification in Human Gut FloraScience, 1983
- Inactivation of Digoxin by the Gut Flora: Reversal by Antibiotic TherapyNew England Journal of Medicine, 1981